Technical Analysis for TROV - TrovaGene, Inc.

Grade Last Price % Change Price Change
grade D 4.01 6.37% 0.24
TROV closed up 6.37 percent on Monday, March 18, 2019, on 54 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Very Strong Down Up Down
See historical TROV trend table...

Date Alert Name Type % Chg
Mar 18 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 18 Outside Day Range Expansion 0.00%
Mar 18 Wide Bands Range Expansion 0.00%
Mar 18 Oversold Stochastic Weakness 0.00%
Mar 15 1,2,3 Pullback Bullish Bullish Swing Setup 6.37%
Mar 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 6.37%
Mar 15 Calm After Storm Range Contraction 6.37%
Mar 15 Narrow Range Bar Range Contraction 6.37%
Mar 15 NR7 Range Contraction 6.37%

Older signals for TROV ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Trovagene Inc., a development stage molecular diagnostic company, focuses on the development and commercialization of proprietary diagnostic technologies for use in patient/disease screening and monitoring in various medical disciplines. The company's urine-based testing platform facilitates to enhance the management of cancer care and women's healthcare. Its proprietary urine-based molecular diagnostic tests are used to detect transrenal DNA and RNA that are cell-free nucleic acids found in urine. The company's technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. In addition, it owns rights to nucleophosmin-1, an informative biomarker for acute myeloid leukemia and mutations in the SF3B1 gene that are to be associated with chemotherapy response in chronic lymphocytic leukemia patients. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene Inc. in January 2010. Trovagene Inc. was founded in 1999 and is headquartered in San Diego, California.
Medicine Biotechnology Cancer Healthcare Clinical Medicine Infectious Diseases Oncology Chemotherapy Tumor Acute Myeloid Leukemia Diagnostic Tests Leukemia Chronic Lymphocytic Leukemia Transplantation Cancer Care Biomarkers
Is TROV a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 2 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 33.12
52 Week Low 2.5362
Average Volume 864,598
200-Day Moving Average 4.6563
50-Day Moving Average 3.5404
20-Day Moving Average 3.5405
10-Day Moving Average 4.062
Average True Range 0.73
ADX 50.96
+DI 52.2515
-DI 10.5626
Chandelier Exit (Long, 3 ATRs ) 7.450000000000001
Chandelier Exit (Short, 3 ATRs ) 4.7262
Upper Bollinger Band 4.872
Lower Bollinger Band 2.209
Percent B (%b) 0.68
BandWidth 75.215365
MACD Line 0.1938
MACD Signal Line 0.1415
MACD Histogram 0.0523
Fundamentals Value
Market Cap 149.45 Million
Num Shares 37.3 Million
EPS -1.25
Price-to-Earnings (P/E) Ratio -3.20
Price-to-Sales 76.85
Price-to-Book 6.46
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.84
Resistance 3 (R3) 4.84 4.56 4.70
Resistance 2 (R2) 4.56 4.35 4.56 4.65
Resistance 1 (R1) 4.29 4.22 4.43 4.29 4.61
Pivot Point 4.01 4.01 4.08 4.01 4.01
Support 1 (S1) 3.74 3.80 3.88 3.74 3.41
Support 2 (S2) 3.46 3.67 3.46 3.37
Support 3 (S3) 3.19 3.46 3.32
Support 4 (S4) 3.19